Tetanus immunoglobulin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intramuscular
Passive immunisation against tetanus
Adult: For the postexposure prophylaxis of patients with tetanus-prone injuries, those who are unimmunised or inadequately vaccinated against tetanus, whose tetanus immunisation history is unknown or uncertain, whose last dose of tetanus vaccine has elapsed for >10 years, or with impaired immunity: In conjunction with a tetanus toxoid-containing vaccine (refer to specific country guideline): 250 international units via deep IM inj. If >24 hours have passed since injury, if the patient is at risk of heavy contamination, or after burns: 500 international units as a single dose via deep IM inj. Administer large volumes (>5 mL) in divided doses at different sites.
Child: Same as adult dose. Administer large volumes (>2 mL) in divided doses at different sites.

Intramuscular
Tetanus
Adult: For the treatment of cases in combination with anti-infective agents, sedatives, and muscle relaxants: 3,000-6,000 international units via deep IM inj. Dosing frequency, interval of administration, and duration of treatment may vary among countries and individual products (refer to country-specific guidelines).
Child: There is limited information regarding the use of this drug in this population, treatment recommendations may vary among countries and individual products (refer to country-specific guidelines).
Chống chỉ định
Hypersensitivity.
Thận trọng
Patient with immunoglobulin A deficiency, risk factors for thrombotic events (e.g. history of vascular disease or thrombotic events, acquired or inherited thrombophilia, prolonged periods of immobilisation, diseases that increase blood viscosity, severe hypovolaemia, hypertension, and diabetes mellitus). Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Immunoglobulin A antibody development, hypersensitivity reaction, shock, arterial and venous thromboembolic events (e.g. MI, stroke, DVT, pulmonary embolism). Rarely, hypotension.
Cardiac disorders: Tachycardia.
Gastrointestinal disorders: Nausea, vomiting, glossitis, buccal ulceration.
General disorders and administration site conditions: Fever, malaise, chills, chest pain, inj site reactions.
Musculoskeletal and connective tissue disorders: Arthralgia, moderate back pain.
Nervous system disorders: Headache, dizziness, tremor.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Erythema, pruritus, facial oedema.
Chỉ số theo dõi
Assess for signs and symptoms of thromboembolic events (e.g. shortness of breath, pain and swelling of the limbs, focal neurological deficits, chest pain).
Tương tác
May decrease the therapeutic efficacy of live vaccines (e.g. measles, rubella, mumps, varicella).
Ảnh hưởng đến kết quả xét nghiệm
May interfere with certain serological tests. May cause a false positive result for red cell alloantibodies (e.g. Coomb's test) and skin tests.
Tác dụng
Description:
Mechanism of Action: Tetanus immunoglobulin is a hyperimmune globulin with a specifically high content of antibodies that neutralise tetanus toxins produced by Clostridium tetani which allows passive immunity to tetanus.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: Approx 2 days.
Excretion: Half-life elimination: Approx 3-4 weeks.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Phân loại MIMS
Vaccin, kháng huyết thanh & thuốc miễn dịch
Phân loại ATC
J06BB02 - tetanus immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Tài liệu tham khảo
Anon. Tetanus Immune Globulin (Human). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/10/2023.

Anon. Tetanus Immune Globulin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 12/10/2023.

Buckingham R (ed). Tetanus Immunoglobulins. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/10/2023.

CSL Behring (NZ) Ltd. Tetanus Immunoglobulin VF 250 International Units, Solution for Intramuscular Injection data sheet 8 June 2022. Medsafe. http://www.medsafe.govt.nz. Accessed 12/10/2023.

Human Tetanus Immunoglobulin 100 International Units/mL Solution for Injection (Bio Products Laboratory Limited). MHRA. https://products.mhra.gov.uk. Accessed 12/10/2023.

Hypertet Injection (Grifols USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/10/2023.

Joint Formulary Committee. Tetanus Immunoglobulin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/10/2023.

Tetagam P Solution for Injection (CSL Behring). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/10/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tetanus immunoglobulin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Purified Antitetanus Serum
  • Tetagam P
  • Tetanus Immunoglobulin Bio Products
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in